Advances in insulin sensitizers

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Disorders

Background:

• Insulin resistance is the primary driver of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
• Understanding insulin production by beta-cells and insulin action is crucial for NIDDM management.
• Defects in insulin production or action are key etiological factors in NIDDM.

Purpose of the Study:

• To review therapeutic interventions for defective insulin action in NIDDM.
• To describe the structure-activity relationships of various novel antidiabetic compounds.
• To elucidate the probable mechanism of action of these compounds via Peroxisome Proliferator-Activated Receptors (PPARs).

Main Methods:

• Literature review of insulin resistance and NIDDM.
• Analysis of structure-activity relationships for diverse chemical classes (e.g., thiazolidinediones, biguanides).
• Examination of compounds targeting PPARs for insulin sensitization.

Main Results:

• Detailed description of structure-activity relationships for numerous antidiabetic agents.
• Identification of novel compounds potentially ameliorating insulin resistance through PPAR activation.
• Compilation of clinical candidates currently undergoing evaluation for NIDDM treatment.

Conclusions:

• Novel compounds, particularly those acting via PPARs, show promise in combating insulin resistance.
• Structure-activity relationship studies guide the development of more effective NIDDM therapeutics.
• Several clinical candidates are advancing, offering potential new treatment avenues for NIDDM.